Biotech Firm With 650% Return Is Norway’s Best Stock This Year
- ArcticZymes benefiting from global drive against coronavirus
- Company uses Arctic enzymes to make medical research products
This article is for subscribers only.
ArcticZymes Technologies ASA, a Norwegian biotechnology company, has seen its share price jump 650% so far this year as it benefits from the pharmaceutical industry’s Covid-19 efforts, making it the Nordic country’s best-performing stock in 2020.
The company, based in Tromso on Norway’s northwest coast, extended its surge on Thursday after it said it would supply materials for a possible vaccine against Covid-19. Its shares closed 20% higher in Oslo, the biggest increase in more than two months.